Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) announced that it presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, held February 24-26, 2026, in London, United Kingdom. The presentation, titled “Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies,” was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference’s Seminar Day program.
Dr. Davis highlighted CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, association with poor clinical outcomes, and limited expression in healthy tissues. Data presented supported the tumor-selective binding profile of Helix’s proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies (nanobody), which demonstrated preferential binding to tumor-expressed CEACAM6. This selective binding profile is designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects, building on the clinical foundation set by Helix’s lead CEACAM6-targeted candidate, L-DOS47, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC).
“CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers,” said Dr. Davis. “Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. Our presentation generated strong interest and discussion among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology.”
A copy of Dr. Davis’ presentation is available on the Company’s website under the “Events and Presentations” page at this link.
World ADC London is a global annual conference dedicated to ADC discovery, development, and commercialization, now in its 16th year. The event brings together over 700 industry stakeholders from more than 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts, as well as a global faculty of over 120 speakers. More information is available at the conference website.
Helix BioPharma is an oncology company whose pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. For more information, visit Helix BioPharma’s website.
This news release contains forward-looking statements within the meaning of applicable Canadian securities laws, subject to risks and uncertainties detailed in the Company’s periodic filings on SEDAR+ at www.sedarplus.ca.
